- Mar 31, 2022
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS THALIDOMIDE NIH National cancer institute - cancer.gov site info This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Thalomid FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/thalidomide MedlinePlus Information A lay language summary of important in
182
- Mar 31, 2022
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS LENALIDOMIDE (REVLIMID) NIH National cancer institute -cancer.gov site info on Lenalidomide This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Revlimid FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/lenalidomide MedlinePlus Information on Lena
433
- Mar 31, 2022
What is Multiple Myeloma? www.uptodate.com
www.uptodate.com - What is Multiple Myeloma? Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics) UPTODATE www.uptodate.com MULTIPLE MYELOMA OVERVIEW Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow. Normally, plasma cells produce antibodies and play a key role in immune function. However, uncontrolled growth of these cells leads to bone pain and fractures, anemia, infections, and other complications. MULTIPLE MYELOMA FE
220
- Mar 31, 2022
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS POMALIDOMIDE (POMALYST) NIH National cancer institute - cancer.gov site info This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Pomalyst FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/pomalidomide MedlinePlus Information A lay language summary o
281
- Mar 30, 2022
Explore MCT: Join us in creating the most comprehensive platform for Myeloma Clinical Trials
The MCT database is constantly being updated. How to Navigate through MCT Website and find high yield topics. You can also search any topic in search bar to find related posts. Welcome to MCT. The MCT database is constantly being updated. Join us in creating the most comprehensive platform for researching Multiple Myeloma Trials, providing accurate and up-to-date information on all myeloma clinical trials, and raising awareness and education about Multiple Myeloma Treatment O
348
- Mar 29, 2022
The Binding Site: Freelite Overview
The Binding Site: Freelite Overview FreeLite Overview Learn more: The Binding Site https://www.youtube.com/c/BindingSite/videos
108
- Mar 18, 2022
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy ELOTUZUMAB (EMPLICITI) NIH National cancer institute - cancer.gov site info This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Empliciti FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/elotuzumab MedlinePlus Information A lay lan
245
- Mar 18, 2022
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Plasma Cell Myeloma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Smoldering Plasma Cell Myeloma Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma This phase II trial
149
- Mar 17, 2022
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy ISATUXIMAB-IRFC (SARCLISA) NIH National cancer institute - cancer.gov site info This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Sarclisa FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/isatuximab-irfc MedlinePlus Information A lay lan
334
- Mar 16, 2022
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj - Monoclonal Ab - Immunotherapy
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj DARATUMUMAB (DARZALEX) NIH National cancer institute - cancer.gov site info This page contains brief information about daratumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name(s): Darzalex FDA Approved: Yes Learn more: https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab MedlinePlus Information A lay language
436
- Mar 15, 2022
Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy
Patient Education: Ciltacabtagene Autoleucel https://www.carvykti.com Ciltacabtagene Autoleucel ( Carvykti) FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an
234
- Mar 10, 2022
Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy
Patient Education: Idecabtagene Vicleucel ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Idecabtagene Vicleucel ( Abecma) NIH National cancer institute - cancer.g
422
- Mar 9, 2022
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT). Minimal Residual Disease (MRD) testing by Clonoseq will be performed in the perip
89
- Mar 9, 2022
NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients
BOREALIS Trial - CMRG 010 NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients This study will evaluate efficacy and tolerability of iberdomide, weekly bortezomib and dexamethasone administered in combination. Sponsor: Canadian Myeloma Research Group ClinicalTrials.gov Identifier: NCT05272826 Official Title: A Single Arm, Multicentre, Open Label Study of Iberdo
98
- Mar 2, 2022
What is a Myeloma Specialist Why do I Need one and How do I Find One? HealthTree University Myeloma
What is a Myeloma Specialist, Why do I Need one, and How do I Find One? HealthTree University Myeloma Dec 13, 2019 Learn more: HealthTree Foundation https://www.healthtree.org https://healthtree.org/myeloma HealthTree University Myeloma https://healthtree.org/myeloma/university https://www.youtube.com/c/HealthTreeUniversity/videos The Myeloma Crowd https://www.myelomacrowd.org Myeloma Crowd by HealthTree https://www.youtube.com/c/MyelomaCrowdbyHealthTree/videos
228
- Mar 2, 2022
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
MagnetisMM-8 NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma Study C1071008 includes 2 parts. The objective of Phase 1b part is to establish the safety profile in order to confirm the monotherapy RP2D in Chinese participants. The Phase 2 part is a single stage design to
133
- Mar 1, 2022
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma Sponsor Pfizer Collaborator In Expanded Access, treating physicians are the Sponsors ClinicalTrials.gov Identifier: NCT05238311 NCT05238311: Pre-approval Single-patient Expanded
131
- Mar 1, 2022
Why is it important to become your own best advocate? HealthTree University Myeloma
Why is it important to become your own best advocate? Why is it important to become your own best myeloma advocate? HealthTree University Myeloma June 2, 2020 In order to make important treatment decisions in conjunction with your doctor you will need to be educated about myeloma terminology and treatment options. Patients that become educated and become their own health advocate tend live longer. Learn more: HealthTree Foundation https://www.healthtree.org https://healthtree
194
- Mar 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
EMN 28 European Myeloma Network EMN28/68284528MMY3005 NCT05257083: Phase 3 : A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6) A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene A
767